Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III

Immutep Limited announced it has received positive feedback from the European Medicines Agency regarding its clinical development program for lead product candidate, eftilagimod alpha, including the planned Phase III trial in MBC.